An agreement undertaken by Litha Pharma (Pty) Ltd, a subsidiary of the Group, will see the business further increasing its generics product portfolio with the Milan based generics development company

Johannesburg, South Africa – 2 November 2011. JSE-listed Litha Healthcare Group Limited, today announced the signing of a definitive agreement with NTC S.r.l, a speciality pharmaceuticals and medical devices supply company. Under the Group’s newly formed generics business unit, the agreement will include generic pharmaceutical products which have already been submitted for approval and release in 2013.

The Italian-based company specialises in niche generics, OTC (over the counter) pharmaceuticals, medical devices and innovative food supplements.  “We have signed an agreement to initially acquire access to some of NTC’s key cardiology generic medicines for registration and launch into the South African market.   However, as part of our effort to build scale and further boost our product pipeline, the agreement will expand to incorporate a broader selection of products from NTC”, says Litha Healthcare Group CEO, Selwyn Kahanovitz.

“We saw NTC as a key strategic partner in our expansion drive of the Pharma Division. They have an excellent track record and have successfully supported extensive product launches in the European market.  Litha has the option in future to access a range of speciality products, some with significant IP advantage and clinical package which will further enhance and differentiate Litha’s generics product portfolio. With their solid regulatory capability and portfolio of speciality products this will help boost our traction and penetration into the retail pharmacy sector”, continues Kahanovitz.

Litha Pharma (Pty) Ltd will manage the submission for approval and distribution of NTC products into the South African market and other serviced territories.

Further company information is available at: www.ntcpharma.it